Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07616453, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Absolute neutrophil count ≥1.5 × 10⁹/L (without growth factor support within 14 days);
Inclusion criterion 1
Platelet count ≥100 × 10⁹/L (without transfusion or supportive therapy within 7 days);
Inclusion criterion 2
Hemoglobin ≥100 g/L (without transfusion within 7 days).
Inclusion criterion 3
Total bilirubin ≤1 × upper limit of normal (ULN);
Inclusion criterion 4
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN in patients with liver metastases);
Inclusion criterion 5
Blood urea nitrogen and serum creatinine ≤1.5 × ULN, and creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula).
Inclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07616453, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria Female patients aged ≥18 and ≤75 years. Histologically confirmed estrogen receptor (ER)-positive (≥10%) and HER2-negative breast cancer, according to the 2018 ASCO/CAP guidelines. HER2-negative status is defined as immunohistochemistry (IHC) 0 or 1+, or IHC 2+ with negative in situ hybridization (ISH) (ISH ratio <2.0), as confirmed by a certified pathology laboratory.
Ki-67 ≥20% assessed on core needle biopsy samples. Newly diagnosed, treatment-naïve patients with stage I-IIIA disease according to the AJCC 8th edition.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Adequate bone marrow function:
- Absolute neutrophil count ≥1.5 × 10⁹/L (without growth factor support within 14 days);
- Platelet count ≥100 × 10⁹/L (without transfusion or supportive therapy within 7 days);
- Hemoglobin ≥100 g/L (without transfusion within 7 days).
Adequate hepatic and renal function:
- Total bilirubin ≤1 × upper limit of normal (ULN);
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN in patients with liver metastases);
- Blood urea nitrogen and serum creatinine ≤1.5 × ULN, and creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula).
Left ventricular ejection fraction (LVEF) ≥50% as assessed by echocardiography. QT interval ≤480 ms on 12-lead electrocardiogram (ECG). Ability and willingness to undergo tumor biopsy. Provision of written informed consent. Exclusion Criteria Prior receipt of any anticancer therapy, including chemotherapy, radiotherapy, targeted therapy, or endocrine therapy.
Concurrent treatment with other anticancer agents. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. Stage IV breast cancer. Breast cancer not confirmed by histopathology. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix.
Severe dysfunction of major organs, including heart, liver, or kidneys. Conditions affecting oral drug administration or absorption, including inability to swallow, chronic diarrhea, or intestinal obstruction.
Participation in another interventional clinical trial within 4 weeks prior to enrollment.
Known hypersensitivity to any component of the study drugs; history of immunodeficiency, including HIV infection, active hepatitis B or C infection, other acquired or congenital immunodeficiency disorders, or history of organ transplantation.
History of significant cardiovascular disease, including but not limited to clinically significant arrhythmias requiring treatment, myocardial infarction, heart failure, or any other cardiac condition deemed unsuitable by the investigator.
Pregnant or breastfeeding women; women of childbearing potential with a positive pregnancy test at baseline, or unwilling to use effective contraception during the study period.
Any serious concomitant disease that, in the investigator's judgment, may compromise patient safety or compliance with the study, including but not limited to uncontrolled hypertension, severe diabetes, or active infection.
History of neurological or psychiatric disorders, including epilepsy or dementia.
Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study.
Quoted from ClinicalTrials.gov, NCT07616453, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07616453, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.